Journey Medical Corporation

Quick facts

Phase 3 pipeline

• DFD-29 · Dermatology
  DFD-29 is a topical antimicrobial agent designed to treat bacterial skin infections by disrupting bacterial cell function.
• glycopyrronium Topical Wipes · Dermatology
  Glycopyrronium is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce sweat gland secretion.

Phase 2 pipeline

• Dose 1 of glycopyrrolate, 2.0% QD
• Dose 1 of glycopyrronium, 2.5% QD · Ophthalmology
  Glycopyrronium is an anticholinergic that works by blocking the action of acetylcholine at muscarinic receptors, leading to reduced salivation and sweating.
• Dose 2 of glycopyrrolate, 3.0% QD
• Dose 2 of glycopyrronium, 3.75% QD
• glycopyrrolate, 1.0%
• glycopyrrolate, 2.0%
• glycopyrrolate, 3.0%
• glycopyrrolate, 4.0%
• Glycopyrronium cloth, 2.4%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Journey Medical Corporation portfolio CI brief
• Journey Medical Corporation pipeline updates RSS